PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C12N 15/12, C07K 14/47, 16/18, G01N 33/566, C12Q 1/68, C12N 15/11, 15/62, A01K 67/027, A61K 38/00

A2

(11) International Publication Number: **WO 00/58473**

(43) International Publication Date: 5 October 2000 (05.10.00)

(21) International Application Number: PCT/US00/08621

(22) International Filing Date: 31 March 2000 (31.03.00)

(30) Priority Data:

60/127,607	31 March 1999 (31.03.99)	US
60/127,636	2 April 1999 (02.04.99)	US
60/127,728	5 April 1999 (05.04.99)	US
09/540,763	30 March 2000 (30.03.00)	US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications

US	60/127,607 (CIP)
Filed on	31 March 1999 (31.03.99)
US	60/127,636 (CIP)
Filed on	2 April 1999 (02.04.99)
US	60/127,728 (CIP)
Filed on	5 April 1999 (05.04.99)
US	09/540,763 (CIP)
Filed on	30 March 2000 (30.03.00)

(71) Applicant *(for all designated States except US)*: CURAGEN CORPORATION [US/US]; 555 Long Wharf Drive, 11th Floor, New Haven, CT 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: SHIMKETS, Richard, A. [US/US]; 191 Leete Street, West Haven, CT 06516 (US). LEACH, Martin [GB/US]; 884 School Street, Webster, MA 01570 (US).

(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: NUCLEIC ACIDS INCLUDING OPEN READING FRAMES ENCODING POLYPEPTIDES; "ORFX"

(57) Abstract

The present invention provides open reading frames ORFX, encoding isolated polypeptides, as well as polynucleotides encoding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX polypeptides, polynucleotides or antibodies. The invention additionally provides methods in which the ORFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

245 250

<210> 5661
<211> 578
<212> DNA
<213> Homo sapiens

<400> 5661
agagctcgaa ggggccatat gacactcctc ccggacccct ggacacacac agccctgggg
60
actggatgcc ttggagcatg caagtccaga gcaccctggg agccctggtg catgggaccc
120
ataacccagt gcacggcaag gacccagcag gaagcaccag ccactggccc cgacctcccg
180
cacccaggac ctgacgggca cttagacaca cacagtggcc tgagctccaa ctccagcatg
240
accacgcggg agcttcagca gtactggcag aaccagaaat gccgctggaa gcacgtcaaa
300
ctgctctttg agatcgcttc agctcgcatc gaggagagaa aagtctctaa gtttgtgatg
360
gggaaatcaa ggcctggaga gatgacttat ccagggtcac gtggcgagac agggacagca
420
ccagaaccag acccgagatg tccacgtcaa agtgacatgc tctgagaggc agcacacaca
480
gaataaccct gcatccaaat tccaggaagc tcttaggggt catccagctg ggcctagggg
540
tgcagggtca gtgctgaggc ctgggcaggg ccgctagc
578

<210> 5662
<211> 148
<212> PRT
<213> Homo sapiens

<400> 5662
Met Thr Leu Leu Pro Asp Pro Trp Thr His Thr Ala Leu Gly Thr Gly
1 5 10 15
Cys Leu Gly Ala Cys Lys Ser Arg Ala Pro Trp Glu Pro Trp Cys Met
20 25 30
Gly Pro Ile Thr Gln Cys Thr Ala Arg Thr Gln Gln Glu Ala Pro Ala
35 40 45
Thr Gly Pro Asp Leu Pro His Pro Gly Pro Asp Gly His Leu Asp Thr
50 55 60
His Ser Gly Leu Ser Ser Asn Ser Ser Met Thr Thr Arg Glu Leu Gln
65 70 75 80
Gln Tyr Trp Gln Asn Gln Lys Cys Arg Trp Lys His Val Lys Leu Leu
85 90 95
Phe Glu Ile Ala Ser Ala Arg Ile Glu Glu Arg Lys Val Ser Lys Phe
100 105 110
Val Met Gly Lys Ser Arg Pro Gly Glu Met Thr Tyr Pro Gly Ser Arg
115 120 125
Gly Glu Thr Gly Thr Ala Pro Glu Pro Asp Pro Arg Cys Pro Arg Gln
130 135 140
Ser Asp Met Leu

What is claimed is:

1. An isolated nucleic acid molecule encoding a polypeptide comprising an amin acid sequence that is at least 85% identical to a polypeptide including an amino acid sequence selected from the group consisting of SEQ ID NO:2*n*, wherein *n* is any integer 1-3161, or the complement thereof.

2. The isolated nucleic acid molecule of claim 1, said molecule hybridizing under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule comprising the sequence of nucleotides selected from the group consisting of SEQ ID NO:2*n*- wherein *n* is any integer 1-3161, or the complement thereof.

3. The isolated nucleic acid molecule of claim 1, said molecule encoding a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ I NO: 2*n*, wherein n is any integer 1-3161, or an amino acid sequence comprising one or more conservative substitutions in the amino acid sequence selected from the group consisting of S ID NO: 2*n*.

4. The isolated nucleic acid molecule of claim 1, wherein said molecule encodes polypeptide comprising the amino acid sequence selected from the group consisting of SEQ I NO: 2*n*, wherein *n* is any integer 1-3161.

5. The isolated nucleic acid molecule of claim 1, wherein said molecule comprise the sequence of nucleotides selected from the group consisting of SEQ ID NO:2*n*-1, wherein any integer 1-3161, or the complement thereof.

6. An oligonucleotide less than 100 nucleotides in length and comprising at least contiguous nucleotides selected from the group consisting of SEQ ID NO:2*n*-1, wherein *n* is a integer 1-3161, or the complement thereof.

7. A vector comprising the nucleic acid molecule of claim 1.

8. The vector of claim 7, wherein said vector is an expression vector.

9 A host cell comprising the isolated nucleic acid molecule of claim 1.

10. A substantially purified polypeptide comprising an amino acid sequence at least 80% identical to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2*n*, wherein *n* is any integer 1-3161.

11. The polypeptide of claim 10, wherein said polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 2*n*, wherein *n* is any integer 1-3161.

12. An antibody that selectively binds to the polypeptide of claim 10.

13. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a therapeutic selected from the group consisting of:

a) the nucleic acid of claim 1;

b) the polypeptide of claim 10; and

c) the antibody of claim 12;

and a pharmaceutically acceptable carrier.

14. A kit comprising in one or more containers, a therapeutically or prophylactically effective amount of the pharmaceutical composition of claim 13.

15. A method of producing the polypeptide of claim 10, said method comprising culturing the host cell of claim 9 under conditions in which the nucleic acid molecule is expressed.

16. A method of detecting the presence of the polypeptide of claim 10 in a sample, comprising contacting the sample with a compound that selectively binds to said polypeptide under conditions allowing the formation of a complex between said polypeptide and said

compound, and detecting said complex, if present, thereby identifying said polypeptide in said sample.

17. A method of detecting the presence of a nucleic acid molecule of claim 1 in a sample, the method comprising contacting the sample with a nucleic acid probe or primer that selectively binds to the nucleic acid molecule and determining whether the nucleic acid probe c primer bound to the nucleic acid molecule of claim 1 is present in the sample.

18. A method for modulating the activity of the polypeptide of claim 10, the methoc comprising contacting a cell sample comprising the polypeptide of claim 10 with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptid

19. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a ORFX-associated disorder, wherein said therapeutic is selected fro the group consisting of:

a) the nucleic acid of claim 1;

b) the polypeptide of claim 10; and

c) the antibody of claim 12.

20. A method for screening for a modulator of activity or of latency or predispositio to an ORFX-associated disorder, said method comprising:

a) contacting a test compound with the polypeptide of claim 10; and

b) determining if said test compound binds to said polypeptide,

wherein binding of said test compound to said polypeptide indicates the test compound is a modulator of activity or of latency or predisposition to an ORFX-associated disorder.

21. A method for screening for a modulator of activity or of latency or predispositio to an ORFX-associated disorder, said method comprising:

a) administering a test compound to a test subject at an increased risk ORFX-associated disorder, wherein said test subject recombinantly expresses a polypeptide encoded by the nucleotide of claim 1;

b) measuring expression the activity of said protein in said test subject;

c) measuring the activity of said protein in a control subject that recombinantly expresses said protein and is not at increased risk for an ORFX-associated disorder; and

d) comparing expression of said protein in said test subject and said control subject, wherein a change in the activity of said protein in said test subject relative to said control subject indicates the test compound is a modulator or of latency of predispostition to an ORFX-associated disorder.

22. The method of claim 20, wherein said test animal is a recombinant test animal that expresses a test protein transgene or expresses said transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein said promoter is not the native gene promoter of said transgene.

23. A method for determining the presence of or predisposition to a disease associated with altered levels of a polypeptide of claim 11 in a subject, the method comprising:

a) measuring the amount of the polypeptide in a sample from said subject; and

b) comparing the amount of said polypeptide in step (a) to the amount of the polypeptide present in a control sample,

wherein an alteration in the level of the polypeptide in step (a) as compared to the control sample indicates the presence of or predisposition to a disease in said subject.

24. The method of claim 23, wherein said subject is a human.

25. A method for determining the presence of or predisposition to a disease associated with altered levels the nucleic acid molecule of claim 1 in a subject, the method comprising:

a) measuring the amount of the nucleic acid in a sample from the mammalian subject; and

b) comparing the amount of said nucleic acid in step (a) to the amount of the nucleic acid present in a control sample,

wherein an alteration in the level of the nucleic acid in step (a) as compared to the co sample indicates the presence of or predisposition to said disease in said subject.

26. The method of claim 25, wherein said subject is a human.

27. A method of treating or preventing a pathological condition associated with a ORFX-associated disorder in a subject, the method comprising administering to said subject polypeptide of claim 10 in an amount sufficient to alleviate or prevent said pathological condition.

28. The method of claim 27, wherein said subject is a human.

29. A method of treating or preventing a pathological condition associated with a ORFX-associated disorder in a subject, the method comprising administering to said subject nucleic acid molecule of claim 1 in an amount sufficient to alleviate or prevent said patholog condition.

30. The method of claim 29, wherein said subject is a human.

31. A method of treating or preventing a pathological condition associated with a ORFX-associated disorder in a subject, the method comprising administering to said subject antibody of claim 12 in an amount sufficient to alleviate or prevent said pathological conditio

32. The method of claim 31, wherein said subject is a human.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 October 2000 (05.10.2000)

PCT

(10) International Publication Number
WO 00/58473 A3

(51) International Patent Classification[7]: C12N 15/12, C07K 14/47, 16/18, G01N 33/566, C12Q 1/68, C12N 15/11, 15/62, A01K 67/027, A61K 38/00

(21) International Application Number: PCT/US00/08621

(22) International Filing Date: 31 March 2000 (31.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/127,607	31 March 1999 (31.03.1999)	US
60/127,636	2 April 1999 (02.04.1999)	US
60/127,728	5 April 1999 (05.04.1999)	US
09/540,763	30 March 2000 (30.03.2000)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	60/127,607 (CIP)
Filed on	31 March 1999 (31.03.1999)
US	60/127,636 (CIP)
Filed on	2 April 1999 (02.04.1999)
US	60/127,728 (CIP)
Filed on	5 April 1999 (05.04.1999)
US	09/540,763 (CIP)
Filed on	30 March 2000 (30.03.2000)

(71) Applicant *(for all designated States except US)*: **CURAGEN CORPORATION** [US/US]; 555 Long Wharf Drive, 11th Floor, New Haven, CT 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SHIMKETS, Richard, A.** [US/US]; 191 Leete Street, West Haven, CT 06516 (US). **LEACH, Martin** [GB/US]; 884 School Street, Webster, MA 01570 (US).

(74) Agent: **ELRIFI, Ivor, R.**; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States *(national)*: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *With international search report.*

— *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

(88) Date of publication of the international search report:
25 January 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NUCLEIC ACIDS INCLUDING OPEN READING FRAMES ENCODING POLYPEPTIDES; "ORFX"

(57) Abstract: The present invention provides open reading frames encoding isolated polypeptides, as well as polynucleotides encoding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX polypeptides, polynucleotides or antibodies. The invention additionally provides methods in which the ORFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.

WO 00/58473 A3

INTERNATIONAL SEARCH REPORT

Internat[illegible]l Application No
PCT/US 00/08621

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/12 C07K14/47 C07K16/18 G01N33/566 C12Q1/68
C12N15/11 C12N15/62 A01K67/027 A61K38/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K G01N A01K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
BIOSIS, EMBASE, MEDLINE, CAB Data, PAJ, EPO-Internal, WPI Data, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	COLE S.T.: "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence." NATURE, vol. 393, 11 June 1998 (1998-06-11), XP002144873 sequence ---	
A	LAMERDIN J.E.: "Sequence analysis of a 3.5 Mb contig in human 19p13.3 containing a serine protease gene cluster." EMEST DATABASE ENTRY, 8 February 1999 (1999-02-08), XP002144874 sequence --- -/--	

[X] Further documents are listed in the continuation of box C.

[ ] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
21 August 2000	23.11.00

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Hix, R

Form PCT/ISA/210 (second sheet) (July 1992)